The latest price target for Collegium Pharmaceutical (NASDAQ:COLL) was reported by Piper Sandler on October 11, 2024. The analyst firm set a price target for $37.00 expecting COLL to rise to within 12 months (a possible 29.33% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Collegium Pharmaceutical (NASDAQ:COLL) was provided by Piper Sandler, and Collegium Pharmaceutical reiterated their neutral rating.

The last upgrade for Collegium Pharmaceutical Inc happened on July 30, 2024 when HC Wainwright & Co. raised their price target to $47. HC Wainwright & Co. previously had a neutral for Collegium Pharmaceutical Inc.

The last downgrade for Collegium Pharmaceutical Inc happened on May 10, 2024 when Needham changed their price target from N/A to N/A for Collegium Pharmaceutical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on October 11, 2024 so you should expect the next rating to be made available sometime around October 11, 2025.

While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a reiterated with a price target of $37.00 to $37.00. The current price Collegium Pharmaceutical (COLL) is trading at is $28.61, which is out of the analyst’s predicted range.